Eli Lilly to Acquire Cancer Biotech Kelonia for Up to $7 Billion
Eli Lilly (LLY) has agreed to acquire privately held cancer drug developer Kelonia Therapeutics for up to $7 billion in cash. The deal, confirmed by the company, was previously reported by The Wall Street Journal and is expected to have significant market implications for the pharmaceutical sector.
Tickers: $LLY
Topics: acquisition cancer drug Eli Lilly Kelonia Therapeutics pharmaceutical